Skip to main content
Fig. 1 | AIDS Research and Therapy

Fig. 1

From: Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV

Fig. 1

Changes in serum lipid profiles. Comparison of serum lipid levels before and 12 months after switching to dolutegravir/lamivudine (DTG/3TC) (a). Comparison of changes in serum lipid profiles between individuals prior on tenofovir (TDF)-based and non-TDF-based regimens (b), as well as those previously exposed to efavirenz (EFV) and DTG regimens (c). TC total cholesterol, TG triglycerides, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol

Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us